Medroxyprogesterone Acetate Inhibits Tumorigenesis in Mouse Models of Oviductal High-Grade Serous Carcinoma
These findings demonstrate that a synthetic progestin, specifically MPA, confers robust protection against HGSC development, while a combination including E2 (E2 + P4) increases risk. This work also illustrates how HGSC GEMMs can be used to compare the chemo-preventive effects of various synthetic progestins on HGSC development in order to prioritize the most effective ones for use in preventing HGSC in both general and high-risk populations.
Authors
- Celeste Leigh Pearce (ORCID: https://orcid.org/0000-0002-8023-7846)
- Maranne Green
- Kathleen R. Cho (ORCID: https://orcid.org/0000-0003-0500-9998)
- Malcolm C. Pike (ORCID: https://orcid.org/0000-0003-4891-1199)
- Eric R. Fearon (ORCID: https://orcid.org/0000-0003-2867-3971)
- Karan Bedi (ORCID: https://orcid.org/0000-0002-7843-738X)
- Rong Wu (ORCID: https://orcid.org/0009-0003-7946-3947)
- Ying Feng
- Yali Zhai (ORCID: https://orcid.org/0000-0001-9792-7336)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- University of Michigan (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-28
- DOI
- https://doi.org/10.3390/cancers17213456
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00